![logo](/logos/ZYNE.webp)
Zynerba Pharmaceuticals, Inc.
NASDAQ:ZYNE
1.3 (USD) • At close October 10, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Zynerba Pharmaceuticals, Inc. |
Symbool | ZYNE |
Munteenheid | USD |
Prijs | 1.3 |
Beurswaarde | 70,121,220 |
Dividendpercentage | 0% |
52-weken bereik | 0.25 - 1.4 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. Armando Anido MBA |
Website | https://www.zynerba.com |
An error occurred while fetching data.
Over Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)